Department of Applied Human Nutrition, Mount Saint Vincent University, Halifax, NS Canada.
South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
Am J Clin Nutr. 2021 Jul 1;114(1):90-100. doi: 10.1093/ajcn/nqab052.
Infantile beriberi-related mortality is still common in South and Southeast Asia. Interventions to increase maternal thiamine intakes, and thus human milk thiamine, are warranted; however, the required dose remains unknown.
We sought to estimate the dose at which additional maternal intake of oral thiamine no longer meaningfully increased milk thiamine concentrations in infants at 24 wk postpartum, and to investigate the impact of 4 thiamine supplementation doses on milk and blood thiamine status biomarkers.
In this double-blind, 4-parallel arm randomized controlled dose-response trial, healthy mothers were recruited in Kampong Thom, Cambodia. At 2 wk postpartum, women were randomly assigned to consume 1 capsule, containing 0, 1.2 (estimated average requirement), 2.4, or 10 mg of thiamine daily from 2 through 24 weeks postpartum. Human milk total thiamine concentrations were measured using HPLC. An Emax curve was plotted, which was estimated using a nonlinear least squares model in an intention-to-treat analysis. Linear mixed-effects models were used to test for differences between treatment groups. Maternal and infant blood thiamine biomarkers were also assessed.
In total, each of 335 women was randomly assigned to1 of the following thiamine-dose groups: placebo (n = 83), 1.2 mg (n = 86), 2.4 mg (n = 81), and 10 mg (n = 85). The estimated dose required to reach 90% of the maximum average total thiamine concentration in human milk (191 µg/L) is 2.35 (95% CI: 0.58, 7.01) mg/d. The mean ± SD milk thiamine concentrations were significantly higher in all intervention groups (183 ± 91, 190 ± 105, and 206 ± 89 µg/L for 1.2, 2.4, and 10 mg, respectively) compared with the placebo group (153 ± 85 µg/L; P < 0.0001) and did not significantly differ from each other.
A supplemental thiamine dose of 2.35 mg/d was required to achieve a milk total thiamine concentration of 191 µg/L. However, 1.2 mg/d for 22 wk was sufficient to increase milk thiamine concentrations to similar levels achieved by higher supplementation doses (2.4 and 10 mg/d), and comparable to those of healthy mothers in regions without beriberi. This trial was registered at clinicaltrials.gov as NCT03616288.
婴儿脚气病相关死亡率在南亚和东南亚仍然很常见。有必要增加产妇硫胺素摄入量,从而增加人乳硫胺素,但所需剂量仍不清楚。
我们旨在估计额外的母亲口服硫胺素摄入剂量,不再显著增加产后 24 周婴儿的乳汁硫胺素浓度,并研究 4 种硫胺素补充剂量对乳汁和血液硫胺素状态生物标志物的影响。
在这项双盲、4 个平行臂随机对照剂量反应试验中,招募了柬埔寨磅通省的健康母亲。产后 2 周,妇女被随机分配在 2 至 24 周期间每天服用 1 粒胶囊,分别含有 0、1.2(估计平均需求量)、2.4 或 10 毫克硫胺素。采用高效液相色谱法测定人乳总硫胺素浓度。采用非线性最小二乘法模型在意向治疗分析中绘制 Emax 曲线。采用线性混合效应模型检验处理组之间的差异。还评估了产妇和婴儿的血液硫胺素生物标志物。
总共,335 名女性中的每一位均随机分配至以下 1 种硫胺素剂量组:安慰剂(n=83)、1.2 mg(n=86)、2.4 mg(n=81)和 10 mg(n=85)。达到人乳中总硫胺素浓度 90%最大值(191 µg/L)所需的估计剂量为 2.35(95%CI:0.58,7.01)mg/d。所有干预组的平均(±SD)乳硫胺素浓度均明显高于安慰剂组(分别为 183±91、190±105 和 206±89 µg/L)(P<0.0001),且彼此之间没有明显差异。
每天补充 2.35 毫克硫胺素即可达到 191 µg/L 的乳汁总硫胺素浓度。然而,22 周内每天补充 1.2 毫克即可将乳硫胺素浓度提高到与较高补充剂量(2.4 和 10 毫克/天)相当的水平,且与无脚气病地区的健康母亲相当。本试验在 clinicaltrials.gov 注册,编号为 NCT03616288。